Hematologic Oncology Update

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications

• Chapters

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKIs (10:23) Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23) Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14) Comparative efficacy of asciminib and other agents used to treat CML (40:01) Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53) Practical care strategies for CML patients; future developments (52:32) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00) Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48) Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10) CME information and select publications

• Chapters

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell Therapy (45:08) Other Novel Therapy Approaches (49:58) EHA 2026 (54:45) CME information and select publications

• Chapters

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00) Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14) CME information and select publications

• Chapters

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics: Introduction (00:00) Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47) Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15) ASCO and EHA 2026 (46:37) CME information and select publications

• Chapters

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16) Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24) Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47) CME information and select publications

• Chapters

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

• Chapters

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1

Featuring perspectives from Dr Mazyar Shadman, including the following topics: The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00) The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31) Zanubrutinib-based therapy for treatment-naïve CLL (12:32) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00) Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22) Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02) CME information and select publications

• Chapters

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45) Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55) Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42) Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24) CME information and select publications

• Chapters

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00) Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41) Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23) Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48) CME information and select publications

• Chapters

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00) Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07) CME information and select publications

• Chapters

Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications

• Chapters

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications

• Chapters

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications

• Chapters